Vitiligo Registry for Adults and Children in the UK
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- The Royal Wolverhampton Hospitals NHS Trust
- Trial code
- NCT06218082
- Record updated
- 15 September 2026
- Original description
Vitiligo is the most common depigmentation disorder affecting around 1% of the population worldwide. Fifty two percent of patients develop vitiligo before the age of 20 and around 80% develop vitiligo before the age of 30 years old.1 Vitiligo often presents in childhood and tends to be a lifelong disease, requiring prolonged courses of phototherapy.Read full original descriptionShow less
Vitiligo Registry for Adults and Children in the UK (VIRTUAL-UK)
Vitiligo is the most common depigmentation disorder affecting around 1% of the population worldwide. Fifty two percent of patients develop vitiligo before the age of 20 and around 80% develop vitiligo before the age of 30 years old.1 Vitiligo often presents in childhood and tends to be a lifelong disease, requiring prolonged courses of phototherapy.
Currently no national or international registry for patients with vitiligo exists. Individual dermatologists maintain a database of such patients, however no coordinated efforts have been made to combine these individual registries into a broader national registry. Finally, recently published British Association of Dermatologists (BAD) guideline for the management of vitiligo, recommended the development of a national registry for people with vitiligo undergoing systemic or light therapy to identify outcomes and safety.
Inclusion: Paediatric and adult patients with vitiligo under management in secondary care; Written informed consent for study participation obtained from the patient or parents / legal guardian, with assent as appropriate by the patient, depending on the level of understanding; Participants consent to participate in long-term follow up and access to all relevant medical records as needed by the study team; Clinical diagnosis of vitiligo made by a dermatologist; Willingness to comply with all study requirements; Competent use of English language, according to patient's age (capable of understanding patient questionnaires).
Exclusion: Insufficient understanding of the study by the patient and/or parent/guardian; Patients with vitiligo/their parents or guardians, who do not provide consent for participation.